tepotinib (BioDeep_00000685115)
代谢物信息卡片
化学式: C29H28N6O2 (492.2273628)
中文名称: 特泊替尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CN1CCC(CC1)COC2=CN=C(N=C2)C3=CC=CC(=C3)CN4C(=O)C=CC(=N4)C5=CC=CC(=C5)C#N
InChI: InChI=1S/C29H28N6O2/c1-34-12-10-21(11-13-34)20-37-26-17-31-29(32-18-26)25-7-3-5-23(15-25)19-35-28(36)9-8-27(33-35)24-6-2-4-22(14-24)16-30/h2-9,14-15,17-18,21H,10-13,19-20H2,1H3
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164000 - c-Met-targeting Agent
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
D000970 - Antineoplastic Agents
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- KEGGdrug: D11717
- PubChem: 25171648
- DrugBank: DB15133
- ChEMBL: CHEMBL3402762
- CAS: 1100598-30-8
- CAS: 1100598-32-0
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Chaofan Wang, Jie Li, Lingzhi Qu, Xia Tang, Xiaojuan Song, Fang Yang, Xiaojuan Chen, Qianmeng Lin, Weibin Lin, Yang Zhou, ZhengChao Tu, Yongheng Chen, Zhang Zhang, Xiaoyun Lu. Discovery of D6808, a Highly Selective and Potent Macrocyclic c-Met Inhibitor for Gastric Cancer Harboring MET Gene Alteration Treatment.
Journal of medicinal chemistry.
2022 11; 65(22):15140-15164. doi:
10.1021/acs.jmedchem.2c00981. [PMID: 36355693] - Liang-Wei Tseng, John Wen-Cheng Chang, Chiao-En Wu. Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report.
International journal of molecular sciences.
2022 Oct; 23(19):. doi:
10.3390/ijms231911809. [PMID: 36233109] - Wenyuan Xiong, Orestis Papasouliotis, E Niclas Jonsson, Rainer Strotmann, Pascal Girard. Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study.
Cancer chemotherapy and pharmacology.
2022 05; 89(5):655-669. doi:
10.1007/s00280-022-04423-5. [PMID: 35385993] - Hesham Salem, Noha Abdal-Karim, Bahaa Omran, Abdel-Rahman Abdel-Gayed, Mazen Atef, Mahmoud Abdelgaleel. Approved spectrofluorimetric strategies for assurance of three modern antineoplastic drugs: tepotinib, sotorasib, and darolutamide in their dose forms and biological liquids utilizing mercurochrome.
Luminescence : the journal of biological and chemical luminescence.
2022 Apr; 37(4):656-664. doi:
10.1002/bio.4206. [PMID: 35142060] - Manja Friese-Hamim, Anderson Clark, Dominique Perrin, Lindsey Crowley, Christof Reusch, Olga Bogatyrova, Hong Zhang, Timothy Crandall, Jing Lin, Jianguo Ma, David Bachner, Jürgen Schmidt, Martin Schaefer, Christopher Stroh. Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases.
Lung cancer (Amsterdam, Netherlands).
2022 01; 163(?):77-86. doi:
10.1016/j.lungcan.2021.11.020. [PMID: 34942492] - Hisashi Tanaka, Kageaki Taima, Tomonori Makiguchi, Junichi Nakagawa, Takenori Niioka, Sadatomo Tasaka. Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation.
Cancer communications (London, England).
2021 01; 41(1):83-87. doi:
10.1002/cac2.12124. [PMID: 33387444] - Andreas Johne, Holger Scheible, Andreas Becker, Jan Jaap van Lier, Peter Wolna, Michael Meyring. Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers.
Investigational new drugs.
2020 10; 38(5):1507-1519. doi:
10.1007/s10637-020-00926-1. [PMID: 32221754] - Friedhelm Bladt, Bettina Faden, Manja Friese-Hamim, Christine Knuehl, Claudia Wilm, Claus Fittschen, Ulrich Grädler, Michael Meyring, Dieter Dorsch, Frank Jaehrling, Ulrich Pehl, Frank Stieber, Oliver Schadt, Andree Blaukat. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2013 Jun; 19(11):2941-51. doi:
10.1158/1078-0432.ccr-12-3247. [PMID: 23553846]